S100P and pancreatic neoplasm: Using data from pancreatic cancer patient samples from The Cancer Genome Atlas (TCGA), we demonstrated that although there was no change in the expression of RAGE, the RAGE ligands, S100P and S100A2, were significantly increased in pancreatic tumors when compared to normal pancreatic tissue (Figure 2A).